Kidney Cancer
Conditions
Keywords
recurrent Wilms tumor and other childhood kidney tumors, stage I Wilms tumor, stage II Wilms tumor, stage III Wilms tumor, stage IV Wilms tumor, stage V Wilms tumor
Brief summary
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. PURPOSE: This laboratory study is looking at DNA variations in the RASSF1A gene in young patients with Wilms' tumor.
Detailed description
OBJECTIVES: Primary * Determine the presence of the A133S polymorphism in the RASSF1A tumor suppressor gene by screening germline DNAs of children with Wilms' tumor. * Determine the inheritance pattern of the A133S polymorphism by evaluating the parents of children who carry this polymorphism. Secondary * Determine the differences in age at diagnosis, stage, histology, site of primary tumor, and outcome, between patients with vs without the A133S polymorphism. * Determine whether the S131F RASSF1A variant is a true polymorphism in these patients. * Determine the polymorphic differences in this gene between these patients based on ethnicity and sex. OUTLINE: This is a multicenter study. Patients are stratified according to age at diagnosis, stage, histology, site of primary tumor, and outcome. Genomic DNA samples are purified from peripheral blood of patients and controls and analyzed by polymerase chain reaction for the RASSF1A gene. DNA is also analyzed from parents of patients with the A133S polymorphism. PROJECTED ACCRUAL: A total of 471 participants (229 Wilms' tumor patients and 200 control participants plus 42 parents) will be accrued for this study.
Interventions
Sponsors
National Cancer Institute (NCI)
Children's Oncology Group
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
Yes
Inclusion criteria
DISEASE CHARACTERISTICS: * Diagnosis of Wilms' tumor OR * Control participants matched for race, sex, and age * No prior or concurrent history of cancer OR * Parents of children involved in the study PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Presence of the A133S polymorphism of the RASSF1A tumor suppressor gene in germline DNAs of children with Wilms' tumor | — |
| Inheritance pattern of the A133S polymorphism in the parents of children who carry this polymorphism | — |
Secondary
| Measure | Time frame |
|---|---|
| Differences in age at diagnosis, stage, histology, site of primary tumor, and outcome between patients with vs without the A133S polymorphism | — |
| Whether the S131F RASSF1A variant is a true polymorphism | — |
| Polymorphic differences in this gene based on ethnicity and sex | — |
Countries
Australia, Canada, Netherlands, New Zealand, Puerto Rico, Switzerland, United States
Outcome results
None listed